PubMed Health⌕ Search

Biomedical subjects

G Peracchia

Publications and source records attributed to G Peracchia.

At least 37 records · Page 2Linked to original sources
PubMed1989

Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. A phase II trial.

Forty-seven consecutive patients with small cell lung cancer (SCLC) were treated with a combination chemotherapy program including 60 mg/m2 of cisplatin (P) on day 1 and 120 mg/m2 of etoposide (E) on day 4, 6, 8, every 21 days. Limited disease (LD) patients, achieving complete response (CR) or partial response (PR) after the three initial courses, received radiotherapy (RT) to the pretreatment primary tumor volume and, those achieving CR, additional RT to the brain. During RT, chemotherapy was administered with 50% dose reduction. Forty-three patients were evaluable for therapeutic response. In the 19 patients with LD, CR was achieved in 63% of patients and the PR rate was 32%. In 24 patients with extensive disease (ED), CR was 34% and PR rate was 54%. Median duration of survival was 66 weeks for LD and 48 weeks for ED. Six patients were disease-free after 2 years. Leucocyte count less than 2000/mm3 was seen in 26% of patients; platelet count less than 50000/mm3 was observed in 9%. Nonhematologic toxicity included universal nausea or vomiting and severe neurotoxicity in 7%. These data indicate that PE combination is a very active front-line regimen in SCLC and could be suggested as one of the reference treatments.

Adult↗
PubMed1986

A method of radiation treatment for advanced neck node metastases.

Thirty-one advanced cervical node metastases (staged N3 according the U.I.C.C. system; 4 N2A, 27N3A according the A.J.C. system) were treated using a particular schedule consisting in two courses: in the first, only the palpable tumor was irradiated with several low energy beams (3.3 mm Al HVL), using as X ray tube operated at 60 kV; in the second course, the whole lymphatic area was treated with 60 Co and conventional fractionation. Palpable disease received 7500 to 10,500 cGy in a overall time of 45-55 days. The local control rate was 87%, without any severe complication. The four (13%) failures were all related to the lowest dose levels.

Humans↗
PubMed1984

Problems in evaluating response of primary breast cancer to systemic therapy.

The evaluation of the response of primary breast cancer to systemic therapy is difficult. Evaluable primary lesions may be assessed both by physical and by mammographic examination. In this study, response to therapy was evaluated after 4 cycles of CMF or CMF plus tamoxifen in 49 patients with locally advanced breast cancer entering a prospective randomized trial. In 35 patients response was evaluated by both physical examination and mammography. In some cases there was disagreement between physical examination and mammography in quantifying the magnitude of response. In 8 of 35 (22.9%), the overall response was overestimated by physical examination versus mammography, while in 3 of 35 (8.6%) the reverse was true. Taking into consideration different criteria in attributing the overall response, i.e. selecting physical examination only, mammography only, or the most favorable or the least favorable response between the two methods of assessment, the objective remission rates were 65.7%, 54.3%, 71.4% and 45.7%, respectively. The data suggest that both physical examination and mammography should be used in evaluating the response of primary breast cancer to a systemic treatment. Should these two methods yield contrasting results, the data obtained with each method should be reported. The best observed response may be employed in determining the overall response.

Adult↗
PubMed1977

[Fractionated low dose radiotherapy].

20 cases of head and neck cancer underwent radiotherapy at low dose rate (2 rad/min) in a clinical trial. Final results were unsatisfactory in terms of both survival and complications. A radiobiological analysis of the high rate of complications is made.

Cobalt Radioisotopes↗